Cited by 109Atrial Fibrillation Management and OutcomesCardiac pacing and defibrillation studiesCardiac Arrhythmias and Treatments

Atrioventricular Nodal Ablation in Atrial Fibrillation: A Meta-Analysis and Systematic Review

Chatterjee, Neal A., Upadhyay, Gaurav A., Ellenbogen, Kenneth A., McAlister, Finlay A., Choudhry, Niteesh K., Singh, Jagmeet P.·2012·Circulation Arrhythmia and Electrophysiology

Abstract

BACKGROUND: In the treatment of patients with refractory atrial fibrillation (AF), the safety and efficacy of atrioventricular nodal ablation (AVNA) versus pharmacotherapy alone remains unclear. Additionally, the impact of AVNA in patients with reduced systolic function is of growing interest. METHODS AND RESULTS: A total of 5 randomized or prospective trials were included for efficacy review (314 patients), 11 studies for effectiveness review (810 patients), and 47 studies for safety review (5632 patients). All-cause mortality was similar between AVNA and medical therapy (3.1% versus 3.3%; relative risk ratio, 1.05; 95% confidence interval [CI], 0.29-3.85). There was no significant difference in exercise duration or ejection fraction (EF) with AVNA relative to pharmacotherapy. In subgroup analysis, patients with baseline systolic dysfunction (116 patients; mean EF, 44%) showed significant relative improvement in EF after AVNA (+4% greater; 95% CI, 3.11-4.89). In pooled observational analysis, AVNA was also associated with significant improvement in EF only in patients with systolic dysfunction (+7.44%; 95% CI, 5.4-9.5). The incidence of procedure-related mortality (0.27%) and malignant arrhythmia (0.57%) was low. At mean follow-up of 26.5 months, the incidence of sudden cardiac death after AVNA was 2.1%. There was significant heterogeneity in quality-of-life scales used; compared with pharmacotherapy, AVNA was associated with significant improvement in several symptoms (palpitations, dyspnea). CONCLUSIONS: In the management of refractory AF, AVNA is associated with improvement in symptoms and quality of life, with a low incidence of procedure morbidity. In patients with reduced systolic function, AVNA demonstrates small but significantly improved echocardiographic outcomes relative to medical therapy alone.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circep.111.967810

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Nowinski K, Gadler F, Jensen-Urstad M, Bergfeldt L. Transient proar- rhythmic state following atrioventricular junction radiofrequency abla- tion: pathophysiologic mechanisms and recommendations for man- agement. Am J Med. 2002;113:596 -602.

Cited by

Sorted by citations

Authors
Chatterjee, N. A., Upadhyay, G. A., Ellenbogen, K. A., McAlister, F. A., Choudhry, N. K., & Singh, J. P.
Affiliations
Brigham and Women's Hospital (US)
Venue
Circulation Arrhythmia and Electrophysiology
Published
2012-02
Volume
5
Issue
1
Pages
68-76
ISSN
  • 1941-3084 (ISSN-L)
  • 1941-3149
OpenAlex
W2084871846
Cited by
109
References
77
Citations by year
2026: 6 · 2025: 9 · 2024: 10 · 2023: 6 · 2022: 15 · 2021: 11 · 2020: 7 · 2019: 6 · 2018: 7 · 2017: 6 · 2016: 6 · 2015: 5 · 2014: 7 · 2013: 4 · 2012: 3
FWCI
3.07
Type
journal article
Language
en
Open access
closed
Locations
  • Circulation Arrhythmia and Electrophysiology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac pacing and defibrillation studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
Keywords
atrioventricular node ablation, refractory atrial fibrillation, pharmacotherapy, reduced systolic function, ejection fraction, all-cause mortality, sudden cardiac death, procedure-related mortality, quality of life, exercise duration, malignant arrhythmias
MeSH terms
Atrial Fibrillation, Atrioventricular Node, Clinical Trials as Topic, Humans, Catheter Ablation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review